deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT00870519

Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Evaluation of [123I] MNI-168 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Sponsor: Institute for Neurodegenerative Disorders

Conditions Alzheimer's Disease
Interventions 123-I MNI-168 I-123-MNI-168
Updated 11 times since 2017 Last updated: Apr 1, 2019 Started: Jan 31, 2009 Primary completion: Dec 31, 2010 Completion: Dec 31, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Assessment of data shows inadequate brain uptake, suggesting the tracer is inadequate as an imaging biomarker of brain amyloid.

Other terminated trials from Institute for Neurodegenerative Disorders

See all terminations from Institute for Neurodegenerative Disorders

Other Alzheimer's Disease trials with similar outcome

Browse all Alzheimer's Disease trials

This PHASE1 trial investigates Alzheimer's Disease and is currently terminated or withdrawn. Institute for Neurodegenerative Disorders leads this study, which shows 11 recorded versions since 2009 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshotTerminated~Aug 2017 – ~May 2018 · 9 months · monthly snapshotTerminated~May 2018 – ~Jun 2018 · 31 days · monthly snapshotTerminated~Jun 2018 – ~May 2019 · 11 months · monthly snapshotTerminated~May 2019 – ~Nov 2020 · 18 months · monthly snapshotTerminated~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1

  5. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE1

▶ Show 6 earlier versions

  1. May 2019 — Nov 2020 [monthly]

    Terminated PHASE1

  2. Jun 2018 — May 2019 [monthly]

    Terminated PHASE1

  3. May 2018 — Jun 2018 [monthly]

    Terminated PHASE1

  4. Aug 2017 — May 2018 [monthly]

    Terminated PHASE1

  5. Feb 2017 — Aug 2017 [monthly]

    Terminated PHASE1

  6. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Institute for Neurodegenerative Disorders
Data source: Institute for Neurodegenerative Disorders

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations